rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    QURE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore

      Analyst sees uniQure's (QURE) AMT-130 as a potential Huntington’s treatment: high-dose therapy slowed cUHDRS decline 80% at 3 years.

      Nov 14Seeking AlphaQURE
      uniQure CEO Defends Huntington’s Therapy Data, Sees Opportunity Ahead of FDA Decision
      Nov 13Yahoo FinanceQURE
      uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod
      Nov 13Yahoo FinanceQURE
      Reduced Loss And Higher Revenue Could Shift The Case For uniQure Stock
      Nov 6Yahoo FinanceQURE
      Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease
      Nov 5Yahoo FinanceQURE
      uniQure N.V. Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceQURE
      uniQure NV (QURE) (Q3 2026) Earnings Call Highlights: FDA Priority Review for AMT-130 and a ...
      Nov 4Yahoo FinanceQURE
      uniQure Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceQURE
      Stifel reiterates uniQure stock rating on FDA priority review
      Nov 4Investing.comQURE
      uniQure Q3 2026 Earnings Call Transcript
      Nov 4BenzingaQURE
      Earnings call transcript: uniQure posts Q3 2026 EPS beat as FDA review advances
      Nov 4Investing.comQURE
      uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
      Nov 4Yahoo FinanceQURE
      UniQure: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceQURE
      Uniqure NV earnings beat by $0.04, revenue fell short of estimates
      Nov 4Investing.comQURE
      uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
      Nov 4Yahoo FinanceQURE
      uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (NASDAQ:QURE)

      uniQure's AMT-130 data likely remains strong enough to support accelerated approval, which isn't priced into the stock at the moment. Read more on QURE stock here.

      Nov 4Seeking AlphaQURE
      All eyes on UniQure earnings amid pivotal Huntington’s therapy review
      Nov 3Investing.comQURE
      UniQure gets an FDA decision date; Teva scraps brain drug study
      Nov 3Yahoo FinanceQURETEVA
      uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE)
      Nov 2BenzingaQURE
      Uniqure's Reversal Continues; Huntington's Drug Lands At FDA

      The FDA said Monday it will make an approval decision on Uniqure's Huntington's gene therapy by May 1. But Uniqure stock fell.

      Nov 2Investor's Business DailyQURE
      FDA to review uniQure's Huntington's gene therapy, decision due on May 2027
      Nov 2ReutersQURE
      Why is uniQure stock sliding today?
      Nov 2Investing.comQURE
      uniQure stock jumps as FDA accepts Huntington’s therapy filing
      Nov 2Investing.comQURE
      UniQure Says FDA Accepts Application for Potential Huntington's Disease Gene Therapy
      Nov 2Yahoo FinanceQURE
      FDA accepts uniQure’s Huntington’s disease gene therapy filing
      Nov 2Investing.comQURE
      uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
      Nov 2Yahoo FinanceQURE
      uniQure (QURE) Stock Could Be Overvalued Despite A Securities Investigation
      Oct 29Yahoo FinanceQURE
      uniQure to Announce Third Quarter 2026 Financial Results
      Oct 28Yahoo FinanceQURE
      UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating
      Oct 15Yahoo FinanceQURE
      uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE)
      Oct 15Seeking AlphaQURE
      Cedar Grove Capital Q3 2026 Portfolio Update
      Oct 7Seeking AlphaQURE
      Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next
      Oct 7Yahoo FinanceQURE
      Barclays Downgrades uniQure to Equal Weight From Overweight
      Oct 5Yahoo FinanceQURE
      Weekly Note: Half The Odds, Six Times The Payoff: Re-Underwriting uniQure After The Four-Year Readout
      Oct 4Seeking AlphaQURE
      RBC Capital cuts uniQure stock price target on trial data
      Oct 2Investing.comQURE
      RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk
      Oct 2Yahoo FinanceQURE
      ClearPoint Neuro: My Speculative Buy Didn't Pan Out, Moving To Hold (NASDAQ:CLPT)

      ClearPoint Neuro faces heightened uncertainty after uniQure's AMT-130 48-month data disappointed. Read more on CLPT stock here.

      Oct 1Seeking AlphaCLPTQURE
      Barclays Sticks to Their Buy Rating for uniQure (QURE)

      Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailQURE
      uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap

      uniQure (NasdaqGS:QURE) is back in focus after new 36- and 48-month data for its Huntington’s gene therapy, AMT-130, sparked sharp swings in the share price and renewed debate about the program. uniQure’s share price has been hit hard in the wake of the mixed AMT-130 update, with a 7-day share price return down 36.95% and a 30-day move down 49.52%, even though the year-to-date share price return is still up 3.29% and the 3-year total shareholder return is very large at roughly 2.6x. This...

      Oct 1Yahoo FinanceQURE
      uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

      The bullish thesis for uniQure’s gene therapy for Huntington's disease is still intact, as evident in consistent and positive TFC data. Click for more on QURE.

      Sep 30Seeking AlphaQURE
      uniQure Plunges on Additional Data From Huntington's Disease Study

      QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.

      Sep 30Yahoo FinanceQURE
      uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far

      uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that cuts both ways.

      Sep 30Yahoo FinanceQURE
      uniQure Highlights Long-Term AMT-130 Huntington’s Data

      Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailQURE
      uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Upgrade)

      uniQure upgraded to speculative Buy as FDA aligns on BLA path for Huntington’s gene therapy. Click for more on QURE stock.

      Sep 30Seeking AlphaQURE
      H.C. Wainwright reiterates uniQure stock rating citing trial data
      Sep 30Investing.comQURE
      uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
      Sep 30MorningstarQURE
      UniQure plunges as Huntington's trial data disappoints investors
      Sep 29ReutersQURE
      uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
      Sep 29Yahoo FinanceQURE
      uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)

      uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.

      Sep 29Seeking AlphaQURE
      uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow (NASDAQ:QURE) 2026-09-29
      Sep 29Seeking AlphaQURE

      This is the newest page. Registered accounts read further back.